| International Myeloma Working Group molecular classification of multiple myeloma: spotlight review R Fonseca, PL Bergsagel, J Drach, J Shaughnessy, N Gutierrez, ... Leukemia 23 (12), 2210-2221, 2009 | 1181 | 2009 |
| Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide … MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, R de Paz, ... The lancet oncology 11 (10), 934-941, 2010 | 589 | 2010 |
| Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study L Rosiñol, A Oriol, AI Teruel, D Hernández, J López-Jiménez, ... Blood, The Journal of the American Society of Hematology 120 (8), 1589-1596, 2012 | 556 | 2012 |
| Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study MV Mateos, JM Hernández, MT Hernández, NC Gutiérrez, L Palomera, ... Blood 108 (7), 2165-2172, 2006 | 533 | 2006 |
| Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation B Paiva, MB Vidriales, J Cerveró, G Mateo, JJ Pérez, MA Montalbán, ... Blood, The Journal of the American Society of Hematology 112 (10), 4017-4023, 2008 | 513 | 2008 |
| Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment … JF San Miguel, MB Vidriales, C López-Berges, J Dıaz-Mediavilla, ... Blood, The Journal of the American Society of Hematology 98 (6), 1746-1751, 2001 | 429 | 2001 |
| Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms BA Walker, CP Wardell, L Melchor, A Brioli, DC Johnson, MF Kaiser, ... Leukemia 28 (2), 384-390, 2014 | 341 | 2014 |
| Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders FM Ross, H Avet-Loiseau, G Ameye, NC Gutierrez, P Liebisch, ... Haematologica 97 (8), 1272, 2012 | 339 | 2012 |
| High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation … B Paiva, NC Gutiérrez, L Rosiñol, MB Vídriales, MÁ Montalbán, ... Blood, The Journal of the American Society of Hematology 119 (3), 687-691, 2012 | 325 | 2012 |
| The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance P Maiso, X Carvajal-Vergara, EM Ocio, R López-Pérez, G Mateo, ... Cancer research 66 (11), 5781-5789, 2006 | 304 | 2006 |
| MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia C Jiménez, E Sebastián, MC Chillón, P Giraldo, J Mariano Hernández, ... Leukemia 27 (8), 1722-1728, 2013 | 300 | 2013 |
| Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials JJ Lahuerta, B Paiva, MB Vidriales, L Cordón, MT Cedena, N Puig, ... Journal of Clinical Oncology 35 (25), 2900-2910, 2017 | 299 | 2017 |
| Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy G Mateo, MA Montalbán, MB Vidriales, JJ Lahuerta, MV Mateos, ... Journal of Clinical Oncology 26 (16), 2737-2744, 2008 | 283 | 2008 |
| Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling NC Gutiérrez, ME Sarasquete, I Misiewicz-Krzeminska, M Delgado, ... Leukemia 24 (3), 629-637, 2010 | 258 | 2010 |
| Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project H Avet-Loiseau, BGM Durie, M Cavo, M Attal, N Gutierrez, J Haessler, ... Leukemia 27 (3), 711-717, 2013 | 257 | 2013 |
| Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma PL Bergsagel, MV Mateos, NC Gutierrez, SV Rajkumar, JF San Miguel Blood, The Journal of the American Society of Hematology 121 (6), 884-892, 2013 | 249 | 2013 |
| A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlyingPLZF/RARA gene rearrangements D Sainty, V Liso, A Cantù-Rajnoldi, D Head, MJ Mozziconacci, C Arnoulet, ... Blood, The Journal of the American Society of Hematology 96 (4), 1287-1296, 2000 | 244 | 2000 |
| Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic … NC Gutierrez, EM Ocio, J de Las Rivas, P Maiso, M Delgado, E Ferminan, ... Leukemia 21 (3), 541-549, 2007 | 221 | 2007 |
| Measurable residual disease by next-generation flow cytometry in multiple myeloma B Paiva, N Puig, MT Cedena, L Rosiñol, L Cordón, MB Vidriales, L Burgos, ... Journal of Clinical Oncology 38 (8), 784-792, 2020 | 215 | 2020 |
| Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t (4; 14) is the most relevant adverse … NC Gutierrez, MV Castellanos, ML Martin, MV Mateos, JM Hernandez, ... Leukemia 21 (1), 143-150, 2007 | 215 | 2007 |
